Clinical Trial Update: The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma [EARLY_Phase 1]

View source ↗

Summary

Early-phase phase 1 study evaluating the combination of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed/refractory mantle cell lymphoma has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• Rituxan (rituximab)
• Treanda (Bendamustine)
• Venclexta (venetoclax)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Mantle Cell Lymphoma, Lymphoma | EARLY_Phase 1 | Status: COMPLETED